Plexus Partners

3 Key Trends Shaping the CDMO Industry in 2024 and Beyond. #cdmo #contractmanufacturing #pharmaceuticals

Haemonetics to buy Attune Medical for $160M. Attune’s device to help cool the esophagus during radiofrequency ablation procedures is a key piece of the acquisition. #Haemonetics #Ablation #RFAblation.

Shape Memory Medical Inc. has secured $38 million in financing to propel the development of custom shape memory polymers for endovascular embolization, a promising field in minimally invasive medical procedures. This funding marks a significant milestone for the company, allowing it to advance its innovative technology aimed at improving patient outcomes and revolutionizing endovascular treatments. With this substantial financial backing, Shape Memory Medical is poised to make strides in the medical industry, showcasing its commitment to pioneering solutions in vascular care. #vascular #peripheralvascular #neurovascular

Accenture Expects 'More Human' Tech, Cardiac Genetic Tests In Walmart; And More #CardiacGenetic #MoreHuman #Accenture

Impulse Dynamics Secures $136M Financing for CCM Therapy. Impulse Dynamics just concluded a significant financing round, raising an impressive $136 million. Impulse specializes in groundbreaking cardiac therapies that aim to revolutionize heart failure management. What makes Impulse Dynamics' technology unique? Cardiac Contractility Modulation (CCM) Therapy. Impulse Dynamics has developed a cutting-edge therapy known as Cardiac Contractility Modulation (CCM). Unlike traditional treatments for heart failure, CCM focuses on improving the heart's contractile function rather than just symptom management. This innovative approach offers promising outcomes for patients with heart failure. How CCM Works: The CCM therapy involves delivering precisely timed electrical pulses to the heart during the absolute refractory period, which is a phase in the heart's cycle where it cannot be stimulated to contract again. These pulses enhance the heart's contractile function, leading to improved cardiac performance and overall heart function. Congrats Doug Nock, Jason Spees and the wider team! #cardiology #cardiacimplantables #heartfailure

Viz.ai's aneurysm diagnostic tool, powered by artificial intelligence (AI), boasts an impressive predictive value of 97.2% in ruling out stroke. This innovative platform utilizes advanced algorithms to accurately detect the presence of aneurysms, providing clinicians with invaluable insights for early intervention and prevention strategies. With its high specificity, Viz.ai's tool offers a promising solution in identifying aneurysms promptly, potentially saving lives by preventing stroke-related complications. This groundbreaking technology signifies a significant advancement in stroke diagnosis and underscores the critical role of AI in enhancing healthcare outcomes. #stroke #artificialintelligence #ai

Boston Scientific gain approval for their WaveWriter spinal cord stimulator (SCS) systems. With this approval, they're now positioned to compete head-to-head with industry leaders like Abbott and Nevro in the SCS market. Boston Scientific's innovation promises to change lives, offering hope and comfort to those who've endured chronic pain. The expanded indication for non-surgical back pain (NSBP) treatment opens new avenues for patients seeking effective pain relief. #SCS #spinalcordstimulation #neurostimulation

Aqemia Secures $32.5 Million for AI-Powered Drug Discovery Platform 💊. Aqemia has successfully raised $32.5 million in funding for its generative AI-powered drug discovery platform. The company intends to utilize this funding to expand its pipeline of drug discovery projects and assets. Aqemia's platform leverages artificial intelligence to identify and design drug candidates, thereby revolutionizing the drug discovery process. This substantial investment underscores the growing interest and confidence in AI-driven approaches within the pharmaceutical industry, signaling significant advancements in drug development and personalized medicine. #pharmaceuticals #drugdiscovery #artificialintelligence

💰 Edwards’ Evoque valve won an early nod from the FDA ✅. Edwards Lifesciences gained early FDA approval for its Evoque transcatheter tricuspid valve replacement system, marking a significant advancement in treating tricuspid regurgitation. The system, comprising a circular device encased in a metal mesh, aims to address tricuspid valve issues non-invasively. This development underscores Edwards' commitment to innovation and improving patient outcomes in cardiovascular care. The heart valve specialist has the chance to shape a new tricuspid market with the first-of-its-kind device, like it did 20 years ago in TAVR, CEO Bernard Zovighian said. #cardiology #structuralheart #tricuspid

Innova Announces Early Commercial Use of Laguna Thrombectomy System. Innova has announced the early commercial use of its Laguna Thrombectomy System, comprising the Malibu Aspiration and the Laguna Thrombectomy devices. This system is designed for the non-surgical removal of emboli or thrombi and is used in patients with venous thromboembolism. The successful commercial deployment of these devices marks a significant milestone in enhancing therapeutic options for venous thromboembolism treatment. #thrombectomy #clotretrieval #vascular